Literature DB >> 20458336

Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses.

Danylo Sirskyj1, Francisco Diaz-Mitoma, Ashkan Golshani, Ashok Kumar, Ali Azizi.   

Abstract

The application of the fields of pharmacogenomics and pharmacogenetics to vaccine design has been recently labeled 'vaccinomics'. This newly named area of vaccine research, heavily intertwined with bioinformatics, seems to be leading the charge in developing novel vaccines for currently unmet medical needs against hypervariable viruses such as human immunodeficiency virus (HIV), hepatitis C and emerging avian and swine influenza. Some of the more recent bioinformatic approaches in the area of vaccine research include the use of epitope determination and prediction algorithms for exploring the use of peptide epitopes as vaccine immunogens. This paper briefly discusses and explores some current uses of bioinformatics in vaccine design toward the pursuit of peptide vaccines for hypervariable viruses. The various informatics and vaccine design strategies attempted by other groups toward hypervariable viruses will also be briefly examined, along with the strategy used by our group in the design and synthesis of peptide immunogens for candidate HIV and influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20458336     DOI: 10.1038/icb.2010.65

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  25 in total

Review 1.  Recent advances in the molecular design of synthetic vaccines.

Authors:  Lyn H Jones
Journal:  Nat Chem       Date:  2015-12       Impact factor: 24.427

2.  Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Authors:  Franco Pissani; Delphine C Malherbe; Harlan Robins; Victor R DeFilippis; Byung Park; George Sellhorn; Leonidas Stamatatos; Julie Overbaugh; Nancy L Haigwood
Journal:  Vaccine       Date:  2012-06-27       Impact factor: 3.641

3.  Human leukocyte antigen associations with humoral and cellular immunity following a second dose of measles-containing vaccine: persistence, dampening, and extinction of associations found after a first dose.

Authors:  Robert M Jacobson; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Gregory A Poland
Journal:  Vaccine       Date:  2011-08-26       Impact factor: 3.641

4.  Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production.

Authors:  Patricio Oyarzún; Bostjan Kobe
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

5.  In silico identification of epitopes from house cat and dog proteins as peptide immunotherapy candidates based on human leukocyte antigen binding affinity.

Authors:  H N Tipu; D Ahmed; S A H Gardezi
Journal:  Iran J Vet Res       Date:  2017       Impact factor: 1.376

6.  Conserved peptide vaccine candidates containing multiple Ebola nucleoprotein epitopes display interactions with diverse HLA molecules.

Authors:  Sahil Jain; Manoj Baranwal
Journal:  Med Microbiol Immunol       Date:  2019-02-21       Impact factor: 3.402

Review 7.  The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; V Shane Pankratz; Richard B Kennedy; Robert M Jacobson; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

Review 8.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

Review 9.  T-cell epitope vaccine design by immunoinformatics.

Authors:  Atanas Patronov; Irini Doytchinova
Journal:  Open Biol       Date:  2013-01-08       Impact factor: 6.411

10.  PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity.

Authors:  Patricio Oyarzún; Jonathan J Ellis; Mikael Bodén; Boštjan Kobe
Journal:  BMC Bioinformatics       Date:  2013-02-14       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.